Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon

B. Marasini, M. L. Biondi, E. Bianchi, P. Dell'Orto, A. Agostoni

Research output: Contribution to journalArticlepeer-review

Abstract

In a double-blind, placebo cross-over study in 14 patients with Raynaud's disease, oral ketanserin 40 mg b.d. for two months reduced the number of digital ischaemic attacks in 36% of the patients, with no difference between primary or secondary cases. Intraplatelet and circulating serotonin concentrations were significantly higher in patients than in controls. During treatment there was a significant decrease in intraplatelet serotonin, but no change in circulating serotonin or in the amount of serotonin released by platelets in vitro. The results suggest that oral ketanserin is of minor help in Raynaud's phenomenon and they support a role for serotonin in the disorder.

Original languageEnglish
Pages (from-to)419-421
Number of pages3
JournalEuropean Journal of Clinical Pharmacology
Volume35
Issue number4
DOIs
Publication statusPublished - Jul 1988

Keywords

  • ketanserin
  • plasma 5-HT
  • platelet 5-HT
  • Raynaud's phenomenon
  • systemic sclerosis

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon'. Together they form a unique fingerprint.

Cite this